High Dose Antioxidant Treatment for Patients with Cystic Fibrosis

Phase 1

• Conditions: Cystic Fibrosis; MedDRA version: 17.0Level: LLTClassification code 10068288Term: Cystic fibrosis pulmonary exacerbationSystem Organ Class: 100000004862; Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

• Registration Number: EUCTR2013-005481-19-DK
• Lead Sponsor: Aarhus University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05-27
• Last Update Posted: 23 May 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

CF patients with verified genotype and FEV1 above 40%.
Clinically stable patients.
No antibiotics or antiinflammatory treatment prior to or under trial
Are the trial subjects under 18? yes
Number of subjects for this age range: 10
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Unstable clinical condition
Unable to perform reliable LFT

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified